MediWound (NASDAQ: MDWD) has announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid—an enzymatic therapy for the removal of eschar in both adult and pediatric patients with deep partial-and full-thickness thermal burns.
According to MediWound, NexoBrid is now authorized in 45 countries worldwide and is recognized as a new standard of care for burn management. The company expects to initiate commercial launch in Australia by the end of 2025.
In a statement, Ofer Gonen, CEO of MediWound, commented, “The TGA approval of NexoBrid marks another important step in expanding access to innovative, non-surgical burn care. Together with our partner (closely held) Balance Medical, we will ensure that burn centers across Australia have access to this therapy. Importantly, this milestone also opens the door to the broader Asia-Pacific region, where we see growing demand for advanced wound and burn treatments.”
